AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03549130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal strip
Description: Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
Study NCT02452060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.4mg/kg infusion
Study NCT02452060 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 0.4mg/kg infusion
Study NCT01858246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bonebridge
Study NCT03776357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VERA clinic
Description: A software system used with the Microsoft Kinect intended to support the physical rehabilitation of adults in the clinic and at home.
Study NCT01648868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (rTMS)
Description: Excitatory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in patients with autism.
Study NCT01648868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (rTMS)
Description: Inhibitory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in healthy controls
Study NCT01199627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration.
Study NCT01199627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B
Description: Group B: 1st dose: 10mg/kg of TXA(tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration.
Study NCT01199627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C
Description: Group C: 1st dose: intravenous infusion over 10 minutes in 100ml of 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration.
Study NCT02706431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Study NCT04903639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sleep study
Description: The polysomnography consists of electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), electromyogram (EMG), pulse oximetry, thoracic and abdominal straps, body posture sensor, nasal thermistor and nasal cannula to assess respiratory flow and pressure and bipolar channel limb movements (tibialis anterior). Electrodes and sensors were attached to patients by sleep physiologist. Data collection was obtained following signal perception by preprocessed computer (DOMINO Software, ver. 2.6.0; SOMNO Medics GmbH).
Study NCT01858246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Anchored Hearing Aid
Study NCT01712412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-9179
Study NCT01712412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03307512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
Study NCT03307512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (Humalog U-100)
Description: Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
Study NCT02561312 — intervention group
Intervention type: OTHER
Intervention: Rapid manual partial exchange transfusion
Description: The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
Study NCT02561312 — intervention group
Intervention type: OTHER
Intervention: Simple Transfusion
Description: The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
Study NCT02892669 — intervention group
Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study
Study NCT03472430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: The TENS machine used in the study will be the Endomed 482 that delivers biphasic pulsed currents using pulse duration of 400 µs and pulse frequencies between 80-100 pulses.
Study NCT03472430 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS machine with electrodes not emitting any impulses.
Description: TENS machine with electrodes not emitting any impulses.
Study NCT00792051 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated influenza vaccine
Description: 0.5ml intramuscular single dose
Study NCT00792051 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5ml intramuscular, one dose
Study NCT01330823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-Carnitine
Description: L-Carnitine, 4g/day, orally (Juice)
Study NCT01330823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tartaric acid same dose like L-Carnitine as placebo
Study NCT03799640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Yoga
Description: Yoga using standard poses and linear movements
Study NCT03799640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-directional Yoga
Description: The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses.
Study NCT03970447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxalisib
Description: Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles
Study NCT03970447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-083
Description: Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.
Study NCT03799640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Control
Description: Lectures on health and fitness
Study NCT05373732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: meditation
Description: meditation practice 20 minutes twice a day at home and attending classes at the clinic.
Study NCT05373732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education control
Description: didactic based classes in CVD risk factor reduction and prevention
Study NCT02865967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care + a-GPS
Description: Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.
Study NCT02865967 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The subjects will be treat for their asthma by their physicians according to usual care.
Study NCT01042977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
Study NCT03986307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acid supplementation
Description: Daily supplementation with omega-3 capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
Study NCT03986307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Resistance exercise training in both supplementation conditions (3 times per week for 12 weeks).
Study NCT03986307 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise
Description: Resistance exercise training in both supplementation conditions (3 times per week for 12 weeks).
Study NCT03986307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - appearance-matched oil supplementation
Description: Daily supplementation with placebo capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
Study NCT00703651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.1 mL, ID. 1 injection/year for 3 years
Study NCT00703651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.1 mL, ID. 1 injection/year for 3 years.
Study NCT00703651 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.5 mL, IM. 1 injection/year for 3 years
Study NCT02716168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared video consultation between patient, general practitioner and oncologist
Description: At the start of the patients chemotherapy treatment a shared video consultation between the patient, general practitioner and oncologist will bee arranged. The video consultation should address distribution of roles, comorbidity, medicine, depression and anxiety symptoms, relatives and social resources.
Study NCT03174535 — intervention group
Intervention type: DRUG
Intervention: Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.
Description: The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.
Study NCT02525120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triojection
Description: Triojection is system intended to deliver a specific amount of ozone to a herniated disc.
Study NCT02525120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical discectomy
Description: Patients will receive surgery to remove the herniated disc material.
Study NCT04055701 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: assesment of thymus volume
Description: assesment of thymus volume
Study NCT04227223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: biochemical measurements
Description: TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
Study NCT04227223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biochemical measurements
Description: TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
Study NCT04487015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MP
Description: The app-based menu planner (MP) given to the participants has an automated carbohydrate periodisation menu planning tool, an educational and motivational nutrition content (infographics, video and text articles), and recipes. Participants using the app will input their training schedule into the app to produce their own menu plans. The behaviour change techniques (BCT) underlying the intervention are goal \& planning, feedback \& monitoring, shaping knowledge, natural consequences, comparison of behaviour, comparison of outcome, associations, repetitions, reward \& threat, regulation and antecedents.
Study NCT03970447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT1021
Description: Dosage Form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri).~Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration.
Study NCT03970447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Dosage Form: Capsule for oral administration Strength: 100 mg Standard Regimen: Dose as confirmed through the dose finding phase orally BID.
Study NCT03970447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: Dosage Form: Solution for intramuscular injection Strength: 11.5 ± 1.0 mg/ml Standard Regimen: For newly diagnosed patients, 36mg/m2. For recurrent disease patients, dose as confirmed through the dose finding phase intramuscularly once a week
Study NCT02010060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Individuals randomized to the aerobic exercise training group will participate in 6 months of supervised exercise training. Exercise dose (expressed in kilocalories per kg per week \[KKW\]) during aerobic training will be 8KKW in week 1, 10KKW in week 2 and 12 KKW in week 3. the exercise dose of 12KKW will be maintained throughout the intervention. Pedometers will be worn by participant in blind-mode throughout the intervention, and removed during exercise training sessions. Participants will enter information about whether they wore their pedometer on the study website. Aerobic exercise group participants will be told to make no conscious alterations to their physical activity or dietary habits
Study NCT02010060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise+ Physical Activity
Description: The Aerobic Exercise+ Physical Activity Group will participate in the same supervised exercise training intervention as the Aerobic Exercise Group, but will also increase the amount of non-exercise physical activity in their daily lives. After week 6 of intervention, participants will incrementally increase Non-Ex PA until they reach an average of 3,000 steps/day above baseline. Non-Ex PA will be increased with moderate physical activity consistent with daily living (i.e. leisurely walking in the evening, walking the dog etc.). Participants will also periodically have life-style counseling sessions with instructors with expertise in behavioral change support to their dietary habits
Study NCT01042977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
Study NCT00384891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synergo + MMC
Description: Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
Study NCT00384891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guérin
Description: Intravesical instillation with BCG (Bacillus Calmette-Guérin)
Study NCT03666182 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT04634721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine injected . This will then be repeated on the contralateral side.
Study NCT00003782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles
Study NCT00003782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles
Study NCT00003782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
Study NCT00204750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bougie Dilation
Description: Bougie dilation will be performed as standard
Study NCT00204750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle-knife incision
Description: Needle-knife incision will be performed
Study NCT03807154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Description: A nine week long ICBT-programme with therapist guidance. Based on cognitive and behavioral techniques that have been tailored to address loneliness.
Study NCT03807154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT
Description: A nine week long internet-based IPT-programme with therapist guidance. Contains three distinct phases: assessment phase (three weeks), focus phase (five weeks, during which the participants will choose from one of four primary problem areas during the three latter weeks), and end phase (one week).
Study NCT03670979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone swaging
Description: osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone
Study NCT04487015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Call
Description: A 30-45 minutes coaching consultation telephone/Skype call from the nutrition coaching to give social support. The BCT underlying the intervention is goal \& planning, social support, natural consequences.
Study NCT04487015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MesC
Description: Nutrition coach-led messaging (MesC) is where the mobile app (MP) has the text messaging feature activated, and the nutrition coach proactively initiates a conversation via text messaging up to three times a week to offer nutrition support to the participant. The BCT underlying the intervention is goal \& planning, social support, natural consequences.
Study NCT03960008 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
Study NCT03960008 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trans-Arterial Chemoembolization (TACE)
Description: First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation
Study NCT03960008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubin
Description: This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
Study NCT06576999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor-based Balance Training
Description: 10 sessions of sensor-based balance training with exergaming feedback. For this training an adaptive integrated audio-visual feedback system composed of five IMUs and a force platform connected wirelessly to a computer has been used. The training protocol include exercises of balance control, encompassing a total of five distinct exercises: i) Latero-lateral load shifting while seated; ii) Load shifting while standing: latero-lateral and antero-posterior, to simulate the balance control performed during the day; iii) Load control during sit-to-stand; iv) Gait swing and loading phase response: to stimulate a correct load shifting during the swing and stance phase; v) Latero-lateral load shifting with knee flexion.
Study NCT06576999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Balance Trainging
Description: 10 sessions of usual balance training. The training includes: gait control exercises, weight shifting, and relies on both stable surfaces (i.e., steps) and unstable surfaces (i.e., oscillating platforms and various-sized fitballs). The protocol encompassed the application of stabilization techniques and the reaching of targets with the upper limb during upright position emulating the activity of daily living.
Study NCT00116974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling and root planing
Study NCT00116974 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing
Study NCT00209261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MINIRIN Oral Lyophilisate
Study NCT00209261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minirin tablet
Study NCT06068101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Secreening test for primary aldosteronism and Confirmatory Testing
Description: Serum aldosterone and plasma direct renin concentrations were measured by a chemiluminescent immunoassay. A positive PA screening was defined by aldosterone > or = 10 ng/dL and aldosterone to renin ratio > or = 2 ng/dL/uUI/mL